| Metric | Grade | Score | Evidence & Notes | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | B+ | 78 | Defensive pharma leader; modest growth; premium valuation offset by dividend yield and brand moat. | 6-12M |
| SA Quality/Value Composite | A− | 82 | P/E 23.0x is elevated vs. historical median (~18−20x) but justified by dividend (2.09% yield) and diversified portfolio. Forward P/E 20.7x more attractive. | 6-12M |
| Zacks Earnings Momentum | C+ | 61 | EPS YoY growth −7.75%; revenue growth +8.06%. Earnings headwind likely from IP expiration and litigation costs; revenue resilience shows underlying demand strength. | 1-3M |
| Institutional & Smart Money Flow | B | 75 | 52-week return +50.6% signals strong institutional accumulation post-2025 trough. Avg volume 7.65M shares shows solid participation. Recent −0.03% daily move indicates equilibrium pricing. | 1-3M |
| Growth Sustainability & Moat | A | 86 | Pharma sector leadership; diversified therapeutic portfolio; strong R&D; brand equity. PEG −2.97 reflects negative EPS growth but solid revenue momentum. Moat very wide. | 6-12M |
| Valuation & Safety (Pre-Penalty) | A− | 80 | Forward P/E 20.7x is reasonable for quality defensive. Beta 0.197 (low volatility). Market cap $617B; enterprise value stable. High valuation flag=false per automated screening. | 6-12M |
| Penalty Overlay | −8 | −8 | Earnings deceleration (−7.75% YoY) typical for mature pharma; ex-dividend date null (data gap); coverage constrained on forward guidance. Minor negative momentum adjustment. | 1-3M |
| CONFIDENCE SCORE | A− | 81 | High-quality live data (quote, metrics, profile complete). Data gaps: earnings date, TTM revenue, ex-dividend date. Institutional-grade disclosure mitigates gaps. | 6-12M |
| Volatility & Drawdown Risk | A+ | 90 | Beta 0.197 = ultra-low systemic risk. 52-week range $169.68−$274.90 = 62% span; current price $256.91 near highs. Ideal defensive hedge. Drawdown risk minimal. | 6-12M |
| Crowding Risk Flag | CAUTION | 65 | 52-week return +50.6% implies strong rally completion. Valuations (P/E 23.0x) at premium. Institutional inflows evident but price now extended. Moderate crowding risk in short term. | 1-3M |
| Horizon | View & Key Drivers |
|---|---|
| 1−3 Months (Near-Term) |
Outlook: HOLD / CAUTIOUS ACCUMULATION (Grade: B) JNJ faces short-term valuation headwinds and crowding risk. At P/E 23.0x with a 52-week gain of +50.6%, price momentum has likely front-run fundamentals. EPS YoY decline (−7.75%) and flat daily price action (−0.03%) suggest consolidation. Dividend support ($5.14/share = 2.09% yield) remains attractive for income investors. Near-term upside capped unless earnings momentum reverses or M&A/strategic news emerges. Watch for Q3 earnings date and forward guidance (data currently unavailable). Zacks momentum score 61/100 warrants caution on new positions; existing holders should hold for dividend. |
| 6−12 Months (Intermediate-Term) |
Outlook: BUY / ACCUMULATE (Grade: A−) Over 6−12 months, JNJ's quality moat, defensive beta (0.197), and dividend growth trajectory support higher conviction. Revenue growth (+8.06% YoY) indicates underlying business resilience; earnings trough likely near. Forward P/E 20.7x offers re-rating upside once EPS stabilizes post-patent headwinds. Institutional flows (+50.6% YoY return) confirm smart money positioning. New product approvals, pipeline maturation, and IP protection in core franchises should drive EPS recovery. Low volatility makes JNJ an ideal core holding for conservative and institutional portfolios. Target: gradual accumulation on dips; fair value range $265−$280 by end of 2026, supported by dividend yield and 3−4% EPS CAGR. |
Key Catalysts: Q3 earnings (date TBD), pipeline approvals, M&A, tax/regulatory clarity.
Risk Factors: Patent expiration, litigation tail, macro slowdown, competitive generics.
Data Confidence: A− (gaps: earnings date, ex-div date, TTM revenue). No material impact on thesis.
ESEN Master AI v3.5-LIVE | Analysis as of 2026-08-07T19:00:57Z | Data Source: Finnhub | Institutional Research Grade
JNJ Analyst Price Target Forecast - ESEN Analytics
JNJ analyst price target: $279.19 average (range $255.0-$305.0), based on 17 Wall Street analysts.
ESEN AI Commentary: Analysts have raised targets following JNJ's execution on new drug launches and resolution of talc litigation uncertainty; the disagreement centers on whether near-term gains in Innovative Medicine and MedTech can sustain double-digit growth into 2030 without M&A, with optimists citing established pipeline momentum offsetting STELARA biosimilar losses while skeptics worry tariff headwinds and drug pricing pressures could constrain 2026 guidance raises.
Analysis by ESEN Analytics Systems (esenglobalinvest.com), an AI-driven US equity research platform covering 5,000+ US stocks.
JNJ Systematic Research
Systematic screening reveals Johnson & Johnson's defensive quality profile through a beta of 0.23, positioning the company as one of the lowest-volatility assets in the pharmaceutical sector. The valuation multiples reflect premium pricing, with a P/E of 29.53 and P/S of 6.34, while the company demonstrates institutional-grade profitability metrics including ROE of 25.74% and net margins of 21.48%. This combination suggests the market prices in sustained competitive advantages and predictable cash generation.
The fundamental model highlights several structural strengths:
- Profitability consistency: ROA of 10.6% and operating margins of 25.73% indicate efficient capital deployment across diversified healthcare segments
- Balance sheet discipline: D/E ratio of 0.59 provides financial flexibility while maintaining moderate leverage
- Revenue expansion: YoY revenue growth of 8.06% demonstrates resilience in a mature industry environment
The screener flags two notable concerns. EPS declined 7.75% year-over-year despite revenue growth, pointing to margin compression or non-operating headwinds requiring deeper examination. Additionally, the current ratio of 1.03 sits near the threshold for adequate liquidity coverage, leaving limited buffer for working capital stress scenarios.
Research perspective relative to peers (LLY, MRK, PFE) shows JNJ trading at a 57% discount to its 52-week high of $274.90, while the P/B multiple of 6.13 indicates the market assigns substantial value to intangible assets and market positioning. The combination of low beta, consistent profitability, and moderate growth characterizes JNJ as a stability-oriented pharmaceutical allocation within systematic portfolios seeking defensive healthcare exposure.
Analysis updated monthly based on systematic screening of fundamentals, profitability, growth, and peer positioning.